Abivax SA American Depositary Shares (ABVX)

Abivax reported a net loss of €100.8M for the first half of 2025, with increased R&D expenses primarily driven by Crohn's Disease clinical program. The company completed a $747.5M public offering and expects to fund operations into Q4 2027.

The article explores two promising biotech companies, Viking Therapeutics and Recursion Pharmaceuticals, highlighting their innovative approaches in weight loss treatments and AI-driven drug development, respectively.

French biotechnology company Abivax SA reported positive Phase 3 clinical trial results for obefazimod, a treatment for ulcerative colitis, causing its stock to surge over 400% in premarket trading on July 23, 2025.

Stay informed of upcoming market events with Seeking Alpha's Stocks to Watch.